General MedicationsINTRAVENOUSGeneric
ZYVOX
LINEZOLID
Standard Dose
400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Key Takeaways
- Primary indication: Review priority: STANDARD Marketing status: Discontinued
- Approval overview ZYVOX is listed in Drugs@FDA under application 021131 (NDA).
- Review priority: STANDARD Marketing status: Discontinued Active ingredient LINEZOLID Form and strength SOLUTION;INTRAVENOUS - 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor PFIZER Submission history Latest submission status date: 2024-06-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZYVOX is listed in Drugs@FDA under application 021131 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LINEZOLID Form and strength SOLUTION;INTRAVENOUS - 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor PFIZER Submission history Latest submission status date: 2024-06-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.